The Mayo Clinic CAR T-Cell Therapy Program offers a new cancer immunotherapy for people with aggressive B-cell non-Hodgkin's lymphoma. The treatment, chimeric antigen receptor (CAR) T-cell therapy, was approved October 2017 by the Food and Drug Administration for certain types of lymphoma.

See full overview

CAR T-Cell Therapy Program